

PNEUMOCOCCAL ETIOLOGY OF PNEUMONIA IN CHILDREN

Nabieva Zumrat Tukhtaevnanabiyeva.zumrat@bsmi.uz*Bukhara State medical institute*

✓ Annotation

Following the widespread introduction of childhood pneumococcal conjugate vaccines (PCVs), a significant impact on pneumonia mortality in children under five years of age has been reported. It is still unknown whether PCVs are expected to reduce pneumonia burden in younger children, particularly ≤ 2 months of age, as current evidence on the role of *S. pneumoniae* in pneumonia etiology in this age group is scarce.

Keywords: *Mycoplasma pneumoniae*, Systematic Review, pneumonia etiology, bacterial pneumonia, children

Introduction

Globally, pneumococcal infections, caused by *Streptococcus pneumoniae* (*Pneumococcus*), are one of the leading causes of morbidity and mortality in children < 5 years of age [1-3]. A variety of clinical syndromes of varying severity are associated with pneumococcus, including pneumonia, meningitis, bacteremia, otitis media and sinusitis. It has been estimated that prior to the introduction of pneumococcal conjugate vaccines (PCVs), diseases caused by pneumococcus were responsible for approximately 600,000 deaths per year globally in children 1-59 months of age [4-7].

Pneumonia is among the leading causes of mortality in children under 5 years of age [8-11]. The main causative pathogens attributable to pneumonia include *Streptococcus pneumoniae*, *Haemophilus influenzae* type B, all of which have vaccine-preventable bacterial causes, and respiratory syncytial virus. Infants and young children are at highest risk for serious disease, with children younger than 4 months being more likely to die. In addition to pneumococcus, a variety of other infectious agents are related to pneumonia in children [12-16].


In the last two decades, more than 140 countries globally have introduced PCVs into national routine immunization schedules. Several studies have demonstrated the impact of PCVs on reducing invasive pneumococcal diseases and hospitalizations due to pneumonias [17-21]. However, pneumonia mortality is the greatest concern for policymakers and donors, and there is limited evidence on the impact of PCVs on pneumonia deaths in children.

Recent evidence from countries in Latin American using secondary mortality data demonstrated the impact of PCVs on pneumonia mortality in children under 5 years of age. Most studies did not include children < 3 months of age assuming that perinatal causes of mortality and other etiologic agents and not pneumococcal disease are responsible for the pneumonia mortality in this age group [18-21]. Nonetheless, this assumption is not fully backed up by the very little available evidence in the literature on the etiology of pneumonia in this age group. Although selected studies have indicated that respiratory viruses are the most common pathogens of pneumonia in infants and toddlers, some investigators have implicated pneumococcus and *Haemophilus* in 4–20% of cases. These findings vary significantly in

developing versus industrialized countries, over time, and depending on laboratory methods used to assess etiologies.

It is still not clear whether pneumococcus is a significant cause of pneumonia in younger children, particularly neonates and children <3 months of age. Whether or not to include children in this age group in impact assessment studies will depend on evidence suggesting whether pneumococcus is a significant etiology of pneumonia and thus an important burden in children under 3 months of age [22-26].

Incidence of Pneumococcal Pneumonia in Children by Age Group



This systematic review aims at summarizing the evidence of the bacterial etiology of respiratory infections in children under 3 months of age, in particular the role of pneumococcus as a significant etiology in this age group.

The aim of the work: to develop an algorithm for timely diagnosis in bacterial etiology of pneumonia in children based on the study of clinical diagnostic markers and serum predictors.

Materials and methods

PCR is considered the new "gold standard" with the higher sensitivity, most assays can detect <100 CFU/mL; The specificity is strong and there is no cross-reactivity when appropriate target selection and amplification conditions are validated. Nucleic acid amplification techniques used to detect MP DNA or RNA differ in the selection of target genes used (e.g. P1 gene, 16S rDNA, 16S rRNA, ATPase operon gene, etc.) (PCR versus isothermal amplification techniques) and the form of detection (conventional versus real-time, single versus multiple) [27-29]. The most problematic issue with PCR is colonization or asymptomatic carriage.

It is extremely rare to compare the performance of PCR methods with different *Mycoplasma pneumoniae* target areas and primers. P1 adhesin gene primers were



found to be more sensitive than 16S rRNA primers, which may be due to the presence of multiple copies of the P1 cell adhesion gene. Studies have compared three different PCR detection methods: the detection method initially described by Bernet, with and without additional hybridization steps for amplicon detection, and the newly developed nested PCR [35-39]. All three PCR methods are reliable in detecting MP in respiratory specimens, but nested PCR is the most sensitive [30-34]. Due to the differences in sample collection, transportation and extraction procedures, input sample size, target genes, primers, cycle parameters, and detection systems, the comparison of sensitivity data for different PCRs becomes complicated.

Clinical treatments

When MP infection is clearly defined, the main treatment method is drug treatment. Rational and standardized use of antibiotics can reduce symptoms and shorten the course of disease.

Mild MPP is more common in school-age children over 5 years old, with a course of 7–10 days, most patients have a good prognosis. The main clinical manifestations are fever and cough, wheezing and dyspnea can be detected in a small number of infants and young children. Imaging findings are bronchitis and bronchopneumonia; only a few patients can develop into severe. Severe MPP refers to the severe condition of MPP, which conforms to any of the following manifestations: high fever ≥ 5 days or fever ≥ 7 days, or wheezing, shortness of breath, dyspnea, chest pain, hemoptysis and other symptoms. These manifestations are related to severe lesions, combined with plastic bronchitis, asthma attacks, pleural effusion and pulmonary embolism; extrapulmonary complications occurred, but did not meet the criteria for critical illness; finger pulse oxygen saturation $\leq 93\%$ when breathing air at rest. The imaging findings were one of the following: large area of pulmonary consolidation; single lung diffuse or double lung multi-leaf segmental bronchiolitis showed. Critically MPP refers to severe MPP with rapid progression, respiratory failure or life-threatening extrapulmonary complications that require life-support treatment.

Conclusion

This review demonstrates that available evidence on etiology of pneumonia in young children, particularly children younger than 3 months of age is based on a variety of studies with non-standardized methodology. Syndromes and case definitions as well as age subgroups included (younger than 7 days and younger than 28 days) vary significantly among studies. Samples collected and tests performed also vary significantly, and also over time, with molecular methods available in more recent studies. Studies also vary in terms of sample size, and time and locality in which it has been conducted. All of these are known factors which may influence the reported etiology and also the ability to identify selected agents. Adequate specimens and testing methods should be used for studies evaluating etiology of pneumonia in children, in particular molecular techniques with higher sensitivity.

Despite the above limitations and challenges, this review reinforces that Gram-positive organisms, in particular *S. pneumoniae*, are still important etiologic agents of pneumonia in children under 3 months of age and should thus be considered when assessing impact of PCV in the children. In addition, viral etiologies are also important, responding for a significant proportion of pneumonia in children younger than 3 months of age.

References:

1. Choi YJ, Kim JH, Koo JK, Lee CI, Lee JY, Yang JH, Ko SY, Choe WH, Kwon SY, Lee CH Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal. Clin . Mol. Hepatol . 2014 ;20:185 –191. doi : 10.3350/cmh.2014.20.2.185.
2. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitara Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. *Journal of Advanced Zoology*, 44(S-2), 3744–3750. Retrieved from <http://jazindia.com/index.php/jaz/article/view/1716>
3. Russ K.B., Stevens T.M., Singal A.K. Acute Kidney Injury in Patients with Cirrhosis. J. Clin. Transl. Hepatol. 2015;3:195–204.
4. Allegretti A.S., Ortiz G., Wenger J., Deferio J.J., Wibecan J., Kalim S., Tamez H., Chung R.T., Karumanchi S.A., Thadhani R.I. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int. J. Nephrol. 2015;2015:108139. doi: 10.1155/2015/108139.
5. Cholongitas E., Senzolo M., Patch D., Shaw S., O’Beirne J., Burroughs A.K. Cirrhotics admitted to intensive care unit: The impact of acute renal failure on mortality. Eur. J. Gastroenterol. Hepatol. 2009;21:744–750. doi: 10.1097/MEG.0b013e328308bb9c.
6. Barbaud A., Waton J., Herbeth B., Bursztejn A. C., Bollaert M., Schmutz J. L., et al. (2014). Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). J. Eur. Acad. Dermatol. Venereol. 28 (4), 491–499. 10.1111/jdv.12130
7. Isakovna, K. D. (2024). DIAGNOSIS AND PROGNOSIS OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C IN HIV-INFECTED CHILDREN. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, 3(5), 127-133.
8. Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. *Journal of Intellectual Property and Human Rights*, 3(4), 19–25. Retrieved from <http://journals.academiczone.net/index.php/jiphr/article/view/2506>
9. Elmurodova A.A. (2023). Viral Hepatitis Delta: An Underestimated Threat. *Texas Journal of Medical Science*, 26, 1–3. Retrieved from <https://zienjournals.com/index.php/tjms/article/view/4610>
10. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitara Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. *Journal of Advanced Zoology*, 44(S2), 3744–3750. Retrieved from <http://www.jazindia.com/index.php/jaz/article/view/1716>
11. Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Texas Journal of Medical Science. – 2022.- P. 86-90
12. Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. *Texas Journal of Medical Science*, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>

17. 13. Abdulloev Mukhridin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. *Texas Journal of Medical Science*, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>
18. 14. Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишнинг профилактикаси ва давосини такомиллаштириш//*Oriental Renaissance: Innovative, educational, natural and social sciences*. -2023.-P.947-953.
19. 15. Oblokulov A.R., M.I. Mukhammadieva. (2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis//*Academicia Globe: Inderscience Research*.-2022.- P. 210-216.
20. 16. Khadieva Dora Isakovna. (2024). Diagnosis and Prediction of Liver Fibrosis in Chronic Viral Hepatitis C in Hiv-Infected. *International Journal of Integrative and Modern Medicine*, 2(6), 89–94. Retrieved from <https://medicaljournals.eu/index.php/IJIMM/article/view/515>
21. 17. Sanokulova Sitara Avazovna. (2023). COVID-19 IN CHILDREN. *Academia Science Repository*, 4(06), 25–32. Retrieved from <https://academiascience.com/index.php/repo/article/view/843>
22. 18. Mukhammadieva Musharraf Ibokhimovna. (2024). TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS COMPLICATED IN VIRUS ETIOLOGY LIVER CIRRHOSIS. *JOURNAL OF EDUCATION, ETHICS AND VALUE*, 3(6), 73–80. Retrieved from <https://jeev.innovascience.uz/index.php/jeev/article/view/723>
23. 19. Sanokulova Sitara Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. *Texas Journal of Medical Science*, 26, 4–9. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4611>
24. 20. Авазовна, С. С. . (2023). Факторы Развития Гепаторенального Синдрома У Больных Циррозом Печени Вирусной Этиологии. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(12), 1–8. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8673>
25. 21. Санокуллова, Ситора Авазовна ОСОБЕННОСТИ ТЕЧЕНИЯ КОНТОГИОЗНЫХ ГЕЛЬМИНТОВ АССОЦИИРОВАННОГО С ЛЯМБЛИОЗОМ // *ORIENSS*. 2023. №2. URL: <https://cyberleninka.ru/article/n/ocobennosti-techeniya-kontogioznyh-gelmintov-assotsirovannogo-s-lyambliozom> (дата обращения: 12.12.2023).
26. 22. Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. *Oriental renaissance: Innovative, educational, natural and social sciences*, 2 (6), 253-257.\
27. 29. A. A., E., A. S., D., & A., M. S. (2022). Modern Approaches to Treatment of Chronic Giardiasis. *Central Asian Journal of Medical and Natural Science*, 3(2), 102-105. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/631>
28. 23. Облокулов, А., & Мухаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИ. *Журнал вестник*

- врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016
29. 24. Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. Central Asian Journal of Medical and Natural Science, 3(3), 438-443. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806>
30. 25. Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES. – 2022.- P. 9-12.
31. 26. Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(1), 41-44.
32. 27. Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // International journal of medical sciences and clinical research 2022;17-21.
33. 28. Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. International Journal of Medical Sciences And Clinical Research, 2(09), 12–16. <https://doi.org/10.37547/ijmscr/Volume02Issue09-04>
34. 29. Raximovich, O. A., Sadilloyevna, J. A., Abdulloyevna, M. S., & Farxodovich, R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>
35. 30. Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 81-86.
36. 31. Abdulloyevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 29–34. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680>
37. 32. Muxtorova, S. A. (2022). Clinical and laboratoriya features of acute respiratory disease in frequently ill children. Web of scientist: International scientific research journal, 1026-1030.
38. 33. Mukhtarova, S. H. (2022). A.(2022) AGE-RELATED FEATURES OF CLINICAL MANIFESTATIONS OF GIARDIASIS. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 17-21.
39. 34. Mukhtarova Shokhida Abdulloevna. (2023). Microbiological Indicators of Patients Infected with SarsCov-2. Texas Journal of Medical Science, 21, 41–45. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4116>
40. 35. Mukhtarova Shokhida Abdulloevna. (2023). CYTOMEGALOVIRUS INFECTIONS IN CHILDREN WITH PRIMARY AND SECONDARY IMMUNE DEFICIENCIES. Academia Science Repository, 4(06), 23–28. Retrieved from <http://academiascience.com/index.php/repo/article/view/832>
41. 36. Aslonova.M.R. (2023). VITAMIN DEFICIENCY CASES RESULTING FROM PARASITIC DISEASES // Galaxy International Interdisciplinary Research Journal.- 2023.-P. 404-409



42. Mukhtorova Shokhida Abdulloevna. (2023). CHARACTERISTIC FEATURES OF THE COURSE OF CITOMEGALOVIRUS INFECTION IN CHILDREN. *Galaxy International Interdisciplinary Research Journal*, 11(4), 484–487. Retrieved from <https://giirj.com/index.php/giirj/article/view/5150..>
43. Raximovich, O. A., Sadilloevna, J. A., Abdulloyevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. *Central Asian Journal of Medical and Natural Science*, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>
44. Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 2(12), 22–28. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678>